NO20092092L - Arylsulfamidderivater og fremgangsmater for anvendelse derav - Google Patents

Arylsulfamidderivater og fremgangsmater for anvendelse derav

Info

Publication number
NO20092092L
NO20092092L NO20092092A NO20092092A NO20092092L NO 20092092 L NO20092092 L NO 20092092L NO 20092092 A NO20092092 A NO 20092092A NO 20092092 A NO20092092 A NO 20092092A NO 20092092 L NO20092092 L NO 20092092L
Authority
NO
Norway
Prior art keywords
disorders
derivatives
arylsulfamide
processes
tautomer
Prior art date
Application number
NO20092092A
Other languages
English (en)
Norwegian (no)
Inventor
Paige Erin Mahaney
Puwen Zhang
Andrew Fensome
Callain Younghee Kim
Eugene John Trybulski
Joseph Peter Sabatucci
An Thien Vu
Eugene Anthony Terefenko
Casey Cameron Mccomas
Michael Anthony Marella
Jr Richard Page Woodworth
Stephen Todd Cohn
Matthew L Crawley
Joel Adam Goldberg
Douglas John Jenkins
Charles William Mann
David John O'neill
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20092092L publication Critical patent/NO20092092L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20092092A 2006-12-12 2009-05-29 Arylsulfamidderivater og fremgangsmater for anvendelse derav NO20092092L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86964406P 2006-12-12 2006-12-12
PCT/US2007/025405 WO2008073459A1 (en) 2006-12-12 2007-12-12 Aryl sulfamide derivatives and methods of their use

Publications (1)

Publication Number Publication Date
NO20092092L true NO20092092L (no) 2009-08-19

Family

ID=39273293

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092092A NO20092092L (no) 2006-12-12 2009-05-29 Arylsulfamidderivater og fremgangsmater for anvendelse derav

Country Status (20)

Country Link
US (4) US7601722B2 (ja)
EP (1) EP2061776A1 (ja)
JP (1) JP2010512401A (ja)
KR (1) KR20090087506A (ja)
CN (1) CN101600701A (ja)
AR (1) AR064318A1 (ja)
AU (1) AU2007333593A1 (ja)
BR (1) BRPI0720289A2 (ja)
CA (1) CA2671844A1 (ja)
CL (1) CL2007003590A1 (ja)
CR (1) CR10866A (ja)
EC (1) ECSP099411A (ja)
MX (1) MX2009006359A (ja)
NO (1) NO20092092L (ja)
PE (1) PE20081395A1 (ja)
RU (1) RU2009121017A (ja)
SV (1) SV2009003295A (ja)
TW (1) TW200843753A (ja)
WO (1) WO2008073459A1 (ja)
ZA (1) ZA200904109B (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009076502A1 (en) * 2007-12-12 2009-06-18 Wyeth Methods for the preparation of hydroxy-substituted aryl sulfamide compounds
GB0813694D0 (en) * 2008-07-25 2008-09-03 Glaxo Group Ltd Compounds
JP2013521290A (ja) * 2010-03-04 2013-06-10 メルク・シャープ・エンド・ドーム・コーポレイション Ｍｇｌｕｒ２の正のアロステリックモジュレータ
CN102838567B (zh) * 2011-06-23 2014-12-31 深圳市湘雅生物医药研究院 一种苯磺酰或苯甲酰哌嗪类化合物及其制备方法和用途
WO2013070660A1 (en) * 2011-11-07 2013-05-16 Emory University Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction
US9867813B2 (en) * 2015-11-17 2018-01-16 Thomas Daly Aminopyridine based buffers with wide buffering ranges, antibiotics and myelin disease therapy
CN107337616A (zh) * 2017-07-13 2017-11-10 上海昕盛医药科技有限公司 一种盐酸班布特罗杂质f的合成方法
CN107445845A (zh) * 2017-08-24 2017-12-08 重庆沃肯精细化工有限公司 一种合成氯法齐明关键中间体n‑(4‑氯苯基)‑1，2‑苯二胺的方法
CA3102129A1 (en) * 2018-06-21 2019-12-26 Cellestia Biotech Ag Process for making amino diaryl ethers and amino diaryl ethers hydrochloride salts
JP2023509452A (ja) 2020-01-03 2023-03-08 バーグ エルエルシー がんを処置するためのｕｂｅ２ｋモジュレータとしての多環式アミド
CN116003261A (zh) * 2022-12-19 2023-04-25 江苏康恒化工有限公司 新型聚氨酯扩链剂2-氨基-2’-氯二苯胺的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3177221A (en) * 1963-02-05 1965-04-06 Mcneilab Inc 2, 1, 3-benzothiadiazoline-2, 2-dioxides
SK94393A3 (en) * 1992-09-11 1994-08-10 Thomae Gmbh Dr K Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
ZA966885B (en) * 1995-08-22 1998-02-16 Du Pont Merck Pharma Substituted cyclic ureas and derivatives thereof useful as retroviral protease inhibitors.
GB9825413D0 (en) * 1998-11-19 1999-01-13 Lilly Co Eli Pharmaceutical compounds
WO2002014315A2 (en) * 2000-08-14 2002-02-21 Ortho Mcneil Pharmaceutical, Inc. Substituted pyrazoles
BR0209128A (pt) * 2001-04-18 2005-11-01 Euro Celtique Sa Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
AU2002367425B2 (en) * 2001-12-28 2006-03-09 Takeda Pharmaceutical Company Limited Preventives/remedies for urinary disturbance
CA2605899C (en) 2005-04-26 2011-02-08 Pfizer Limited Triazole derivatives as vasopressin antagonists
CA2624096A1 (en) * 2005-09-29 2007-04-12 Wyeth Benzothiadiazolyphenylalkylamine derivatives for use in the treatment of conditions ameliorated by monoamine reuptake

Also Published As

Publication number Publication date
CA2671844A1 (en) 2008-06-19
BRPI0720289A2 (pt) 2014-02-04
PE20081395A1 (es) 2008-09-17
TW200843753A (en) 2008-11-16
US20080194654A1 (en) 2008-08-14
ECSP099411A (es) 2009-07-31
MX2009006359A (es) 2009-06-26
US7601722B2 (en) 2009-10-13
US20080161366A1 (en) 2008-07-03
AR064318A1 (es) 2009-03-25
RU2009121017A (ru) 2011-01-20
EP2061776A1 (en) 2009-05-27
CN101600701A (zh) 2009-12-09
US20100029641A1 (en) 2010-02-04
AU2007333593A1 (en) 2008-06-19
KR20090087506A (ko) 2009-08-17
ZA200904109B (en) 2010-04-28
SV2009003295A (es) 2009-10-29
CR10866A (es) 2009-07-14
JP2010512401A (ja) 2010-04-22
CL2007003590A1 (es) 2008-02-29
US20080167303A1 (en) 2008-07-10
WO2008073459A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
NO20092092L (no) Arylsulfamidderivater og fremgangsmater for anvendelse derav
WO2008073956A3 (en) Cyclic sulfonamide derivatives and methods of their use
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
NO20084652L (no) Deazapuriner anvendelige som inhibitorer av januskinaser
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
MX2012007273A (es) Pteridinonas como inhibidores de la quinasa tipo polo.
MX2009002274A (es) Compuestos de enlace fxr heterociclicos.
JO3007B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
ECSP10010035A (es) Amidas heterocíclicas y sus métodos de uso
MX2010002258A (es) Compuestos terapeuticos de isoxazol.
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
MX2010005861A (es) Agonistas novedosos de los receptores de glucocorticoides.
EA200801738A1 (ru) Пиперидиноилпирролидиновые агонисты меланокортинового рецептора 4 типа
NO20085257L (no) Purinonderivater som HM74a-agonister
NO20085099L (no) Puritonderivativer som HM74A agonister
WO2009036996A3 (en) Small molecule bradykinin b1 receptor antagonists
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
EP2091328A4 (en) SPIROPIPERIDININHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER DISEASE
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
ATE520651T1 (de) Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
NO20085051L (no) Behandling av gastrointestinale forstyrrelser med CGRP-antagonister
MY173696A (en) Cyclic amide derivatives as inhibitors of 11-beta- hydroxysteroid dehydrogenase and uses thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application